SCHEMBL4094148

SCHEMBL4094148

C=Cc1ccc(Oc2ncc(Br)cn2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
FFAR1 O14842 1/20 0.40
TUBB4A P04350 2/20 0.38
TUBB P07437 2/20 0.38
TUBA3C P0DPH7 2/20 0.38
TUBA1B P68363 2/20 0.38
TUBA4A P68366 2/20 0.38
TUBB4B P68371 2/20 0.38
TUBB3 Q13509 2/20 0.38
TUBB2A Q13885 2/20 0.38
TUBB8 Q3ZCM7 2/20 0.38
TUBA3E Q6PEY2 2/20 0.38
TUBA1A Q71U36 2/20 0.38
TUBA1C Q9BQE3 2/20 0.38
TUBB6 Q9BUF5 2/20 0.38
TUBB2B Q9BVA1 2/20 0.38
TUBB1 Q9H4B7 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6670705 0.77 ALDH1A1 (0.52) ALDH1A1KDM4ESMN1; SMN2LMNACHRNB2
SCHEMBL11153430 0.76 MEN1 (0.62) ALDH1A1KDM4ESMN1; SMN2FFAR1TUBB4A
SCHEMBL22404982 0.76 NPSR1 (0.57) SMN1; SMN2LMNAFFAR1TUBB4ATUBB
SCHEMBL3979224 0.76 APP (0.43) ALDH1A1KDM4ESMN1; SMN2LMNAFFAR1
SCHEMBL11080118 0.76 MEN1 (0.50) FFAR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL24156362 0.76 MEN1 (0.44) ALDH1A1KDM4ESMN1; SMN2LMNAFFAR1
SCHEMBL3977514 0.76 ALDH1A1 (0.57) ALDH1A1KDM4ESMN1; SMN2LMNAFFAR1
SCHEMBL2313930 0.75 MEN1 (0.55) ALDH1A1SMN1; SMN2FFAR1TUBB4ATUBB
SCHEMBL296908 0.73 ALDH1A1 (0.65) ALDH1A1KDM4ESMN1; SMN2LMNACHRNB2
SCHEMBL18554989 0.73 FFAR1 (0.40) ALDH1A1KDM4ESMN1; SMN2LMNAFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-11-26 US disclosed
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-11-26 US disclosed
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-11-26 US disclosed
WO-2009058937-A2 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-05-07 WO disclosed
WO-2009058937-A2 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION AHR, MALT1, ABL1 ALDH1A1 1591/4885KDM4E 769/4885SMN1; SMN2 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.